16 active not recruiting, 15 completed, 7 terminated, 5 recruiting. 50 Phase 1, 21 Phase 2.
Follow CT-P10: new trials by email Literature Review of CT-P10 trials Research Report on CT-P10
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-10-28 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2024-01-29 | 2026-02-27 |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 20 | 2022-09-02 | 2026-05-06 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone - Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | Yazeed Sawalha | 38 | 2021-11-16 | 2026-07-02 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | University of California, Davis | 36 | 2021-09-17 | 2026-10-26 |
| Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test - Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 47 | 2021-05-24 | 2026-10-19 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Venetoclax, Lenalidomide, Rituximab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | Thomas Jefferson University | 4 | 2020-10-16 | 2026-10-02 |
| Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib - Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma | Phase 1 | Active not recruiting | Mayo Clinic | 50 | 2020-06-15 | 2026-02-02 |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma Copanlisib, Gemcitabine, Carboplatin - Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | University of Washington | 12 | 2020-03-31 | 2023-06-29 |
| Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Bendamustine, Cyclophosphamide - Hematopoietic and Lymphoid System Neoplasm | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 25 | 2020-03-13 | 2026-07-16 |
| Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda Rituximab and Hyaluronidase Human, Cyclophosphamide, Vincristine - Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 18 | 2019-10-24 | 2024-01-03 |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - CD19 Positive, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-10-03 | 2020-01-29 | |
| Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant Busulfan, Gemcitabine, Melphalan - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 50 | 2019-09-13 | 2026-07-30 |
Showing 20 of 50. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (18) · Lymphoma, Mantle-Cell (10) · Lymphoma, Follicular (9) · Lymphoma, B-Cell (7) · Lymphoma, Non-Hodgkin (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Hodgkin Disease (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, B-Cell, Marginal Zone (5) · Burkitt Lymphoma (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, T-Cell (3) · Myelodysplastic Syndromes (3) · Blast Crisis (2) · Composite Lymphoma (2)
M.D. Anderson Cancer Center (15) · National Cancer Institute (NCI) (14) · City of Hope Medical Center (3) · OHSU Knight Cancer Institute (3) · Mayo Clinic (2) · Northwestern University (2) · University of Washington (2) · Academic and Community Cancer Research United (1) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Nathan Denlinger (1) · Roswell Park Cancer Institute (1) · Thomas Jefferson University (1) · University of California, Davis (1) · University of Nebraska (1)
United States (48) · Uganda (1)
Alex F Herrera (1) · Alvaro J Alencar (1) · Bouthaina S Dabaja (1) · Catherine S Diefenbach (1) · Chaitra S Ujjani (1) · Chitra Hosing (1) · Craig Sauter (1) · Daniel O Persky (1) · Edward A Neuwelt (1) · Elias Jabbour (1) · Elizabeth Budde (1) · Elizabeth L Budde, MD,PhD (1) · Farhad Ravandi-Kashani (1) · Francisco Hernandez-ILizaliturri (1) · Grzegorz S Nowakowski (1)
PMID 34515338, PMID 23834234, PMID 25145344, PMID 27118452, PMID 27697771, PMID 29386196, PMID 32430507, PMID 35787017, PMID 36841758, PMID 37632592, PMID 38207208, PMID 39319495, PMID 40184567, PMID 40706069
P30CA016672 (3), P30CA033572 (3), UM1CA121947 (3), UM1CA186717 (3), P30CA060553 (2), U10CA180821 (2), 2015 (1), P30CA008748 (1), P30CA013330 (1), P30CA015083 (1), P30CA015704 (1), P30CA036727 (1), P30CA051008 (1), P30CA069533 (1), P30CA093373 (1)